文献速递痛风与晶体性关节病

焦磷酸钙沉积研究结局域的范围综述:OMERACT CPPD工作组报告

Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group.
PubMed 文献 · Semin Arthritis Rheum · 2020-05-30

该范围综述由OMERACT CPPD工作组开展,检索1946年至2020年1月的文献,纳入112篇研究(109项观察性研究、3项随机对照试验),将报告结局映射至OMERACT Filter 2.1框架,发现最常报告的结局域为影像学表现、关节疼痛和治疗反应,而生活影响、社会资源利用和长寿相关域报告极少。

要点

  • CPPD研究结局报告异质性大,缺乏经过验证的结局域和测量工具。
  • 最常报告的结局域为影像学关节损伤(59项研究)和关节钙化(28项研究)。
  • 生活影响、社会资源利用和长寿相关结局域极少被报告。

核心结论

  • CPPD研究结局报告存在显著异质性,最常报告影像学表现、关节疼痛和治疗反应域。

研究设计与样本

  • 范围综述检索Medline、EMBASE和CENTRAL数据库1946年1月1日至2020年1月7日文献,纳入112篇研究(109项观察性研究、3项随机对照试验),方案注册于PROSPERO(CRD: 42019137075)。

主要发现

  • 影像学关节损伤报告于59项研究,影像学关节钙化报告于28项研究。
  • 关节疼痛报告于26项研究,治疗反应报告于23项研究,治疗副作用报告于15项研究。
  • 关节液或血液炎症(ESR或CRP)报告于12项研究,关节液标志物报告于4项研究,其他血液标志物报告于2项研究。
  • 整体功能报告于14项研究,关节肿胀报告于12项研究,关节活动度报告于10项研究。

关键数值与推荐

  • 结局映射至22个域,采用OMERACT Filter 2.1定义的核心领域和域。

临床怎么用

  • 提示CPPD研究需统一结局域,优先关注影像学、疼痛和治疗反应等高频域,并补充生活影响等被忽视域。

局限性

  • 仅纳入至2020年1月的文献,以观察性研究为主(109/112),随机对照试验仅3项。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although calcium pyrophosphate deposition (CPPD) is common, there are no validated outcome domains and/or measurements for CPPD studies. The aim of this work was to identify domains that have been reported in prior clinical studies in CPPD, to inform the development of a core set of domains for CPPD studies. METHODS: We performed a scoping literature review for clinical studies in CPPD, searching in Medline (via PubMed), EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) databases; published from January 1, 1946 to January 7, 2020. All reported outcomes and study design data were extracted and mapped to the core areas and domains as defined by the OMERACT Filter 2.1.The protocol was registered on PROSPERO (CRD: 42019137075; 09-07-2019). FINDINGS: There were 112 papers identified, comprising of 109 observational studies and three randomized controlled trials. Most studies reported clinical presentations of OA with CPPD or acute CPP crystal arthritis. Outcomes that mapped to 22 domains were identified; the most frequently reported measures mapped to the following domains/sub-domains: imaging (joint damage on imaging tests - 59 studies; joint calcification on imaging tests - 28 studies), joint pain (26 studies), response to treatment (23 studies), side effects of treatment (15 studies), inflammation in the joint fluid or blood (ESR or C-reactive protein - 12 studies; synovial fluid markers - 4 studies; other blood markers - 2 studies), overall function (14 studies), joint swelling (12 studies) and range of joint movement (10 studies). Very few studies mapped to domains related to life impact, societal/resource use or longevity. CONCLUSION: There is substantial variability in outcomes reported in CPPD studies. Outcomes that map to imaging manifestations, joint pain and response to treatment domains are most often reported.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Cai K, Fuller A, Hensey O, et al. Outcome domains reported in calcium pyrophosphate deposition studies: A scoping review by the OMERACT CPPD working group. Semin Arthritis Rheum. 2020. PMID: 32521326. doi:10.1016/j.semarthrit.2020.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。